JPRN-jRCT2031230317招募中3 期
A phase III study (physician-initiated clinical trial) to evaluate the efficacy and safety of sirolimus for epileptic seizures with focal cortical dysplasia type II
Kato Mituhiro0 个研究点目标入组 20 人开始时间: 2023年9月4日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 1age old 至 ot applicable（—）
- 性别
- All
入选标准
- •(1) Patients with a diagnosis of focal cortical dysplasia type II (including hemimegalencephaly) based on neuroimaging findings by head MRI within 156 weeks prior to enrollment or brain pathology prior to enrollment
- •(2) Patients aged 1 year or older at the time of consent
- •(3) Patients diagnosed with focal motor onset seizures (with motor signs which are able to be confirmed by others) or focal to bilateral tonic-clonic seizures associated with FCD based on the operational classification of seizure types by the International League Against Epilepsy (ILAE) 2017 (Appendix 1)
- •(4) Patients who have been treated with at least 2 antiepileptic drugs for at least 26 weeks since the diagnosis of epilepsy
- •(5) Patients on treatment with 1 to 4 antiepileptic drugs at the time of consent
- •(6) Patients whose dosage and administration of antiepileptic drugs has been constant for 8 weeks prior to enrollment
- •(7) Patients whose vagal nerve stiumulation therapy stimulation conditions have been constant for 8 weeks prior to enrollment
- •(8) Patients with at least 2 focal motor onset seizures (with motor signs which are able to be confirmed by others) or focal to bilateral tonic-clonic seizures during the 28-day baseline observation period
- •(9) Patients who provide written consent to participate in this study from the patient or a surrogate (parent or legal guardian).
排除标准
- •(1)Patients who have participated in another clinical trial within 12 weeks prior to obtaining consent
- •(2)Patients who have taken sirolimus or everolimus within 52 weeks prior to enrollment
- •(3)Patients in whom neither the patient nor a surrogate can accurately record the number and duration of seizures
- •(4)Patients suspected of having progressive brain lesions on computed tomography(CT)or magnetic resonance imaging(MRI)performed to date
- •(5)Patients who have undergone neurosurgery for epilepsy(focal resection, cortical resection, functional hemispherectomy, corpus callosotomy, vagus nerve stimulation, or electrode implantation)within 26 weeks prior to enrollment
- •(6)Patients who are taking or have taken felbamate or vigabatrin within 26 weeks prior to enrollment
- •(7)Patients on a ketogenic diet
- •(8)Patients with previous suicide attempts
- •(9)Patients with a history or complications of substance abuse(including alcohol abuse)
- •(10)Patients of childbearing potential or male patients with a partner of childbearing potential who cannot agree to use contraception from the time of consent until 12 weeks after completion of study medication, patients who are pregnant or lactating, or patients who may be pregnant
- •(11)Patients with any of the following on clinical examination during the baseline observation period
- •-Patients whose AST or ALT levels are 2.5 times or more than the reference value
- •-Leukocytes count less than 3000 cells/mm3 or Ht less than 30%, platelets less than 80,000/mm3 or neutrophils less than 1000/mm3
- •-HBs antigen-positive patients, HBs antibody-positive or HBc antibody-positive patients except after hepatitis B vaccination, or patients with active hepatitis C(HCV antibody-positive patients are excluded if they are inactive and have normal liver function values)
- •-Patients with poorly controlled dyslipidemia, i.e., serum triglycerides >= 500 mg/dL or LDL cholesterol >= 190 mg/dL despite treatment for dyslipidemia
- •-Patients with abnormal renal function. That is, estimated glomerular filtration rate(eGFR)less than 30 mL/min/1.73 m2
- •(12)Patients with concomitant arrhythmias requiring treatment
- •(13)Patients with concomitant cardiac or renal insufficiency that may affect hemodynamics
- •(14)Patients with concomitant immunodeficiency
- •(15)Patients with fever over 38 degree celsius or active infection
- •(16)Patients with interstitial pneumonia at the time of enrollment
- •(17)Patients who have undergone surgery(surgery requiring intracorporeal invasion or more than 3 stitches, including biopsy)within 12 weeks prior to enrollment.
- •(18)Patients who are judged to be inappropriate for this study by the investigator(s).
研究者
相似试验
进行中（未招募）
不适用
Prelude A Phase 3 Clinical Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin - NDEUCTR2005-004630-41-ITELI LILLY459
招募中
3 期
A Phase 3 clinical study to determine the pharmacokinetics, safety and efficacy of rVWF:rFVIII and rVWF in the treatment of bleeding episodes in subjects diagnosed with von Willebrand diseaseCoagulation disorderHereditary deficiency of Von Willebrand Factor in blood1006447710005330NL-OMON38008Baxter4
进行中（未招募）
不适用
Assessment of the efficacy of PGL4001 in repeated treatment courses on reducing symptoms of uterine fibroids causing heavy menstrual periodsterine myomas are benign, monoclonal, hormone-sensitive, smooth muscle tumours of the uterus. They are the most common tumour of the female reproductive tract in pre-menopausal women and mostly asymptomatic affecting approximately 40% of women between 35 and 55 years. When symptomatic, the main symptoms are heavy uterine bleeding, abdominal pressure, abdominal pain, increased urinary frequency and infertility.MedDRA version: 14.0Level: LLTClassification code 10046801Term: Uterine myomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-019497-32-PLPregLem S.A.200
进行中（未招募）
不适用
PGL4001 Efficacy Assessment in Reduction of symptoms due to uterine Leiomyomataterine myomas are benign, monoclonal, hormone-sensitive, smooth muscle tumours of the uterus. They are the most common tumour of the female reproductive tract in pre-menopausal women and mostly asymptomatic affecting approximately 40% of women between 35 and 55 years. When symptomatic, the main symptoms are heavy uterine bleeding, abdominal pressure, abdominal pain, increased urinary frequency and infertility.MedDRA version: 14.0Level: LLTClassification code 10046801Term: Uterine myomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-018999-25-ATPregLem S.A.200
进行中（未招募）
1 期
A Phase III, multicentre, clinical study investigating the efficacy and safety of 3-months open-label treatment with PGL4001, followed by a randomised, double-blind placebo controlled period of 10 days treatment with progestin, in subjects with myomas and heavy uterine bleeding. - PEARL III: PGL4001 Efficacy Assessment in Reduction of symptoms due to uterine Leiomyomataterine myomas are benign, monoclonal, hormone-sensitive, smooth muscle tumours of the uterus. They are the most common tumour of the female reproductive tract in pre-menopausal women and mostly asymptomatic affecting approximately 40% of women between 35 and 55 years. When symptomatic, the main symptoms are heavy uterine bleeding, abdominal pressure, abdominal pain, increased urinary frequency and infertility.MedDRA version: 12.1Level: LLTClassification code 10046801Term: Uterine myomaEUCTR2010-018999-25-BEPregLem S.A.200